A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a ...

Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

A recent investigation by The New York Times revealed that two pharmaceutical companies, Eisai and Eli Lilly, withheld critical genetic risk information from volunteers during clinical trials for ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were presented ...

STOCKHOLM, Oct. 31, 2024 /PRNewswire/ --BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a Biologics License ...